Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
Author: Manny Vazquez, Senior Director Clinical Data Strategy, Veeva The number of data points collected in clinical trials has tripled…
Partner Content
-
-
Why researchers are bringing cardiovascular trials to the heart of the community
Cardiovascular disease (CVD), a broad term for conditions affecting the heart and blood vessels, remains the leading cause of death…
-
Meet the new EmVenio at OCT events across 2026
Looking towards 2026, clinical trial teams continue to face challenges surrounding recruitment and retention, while many patients continue to confront…
-
Why the industry needs to rethink its approach to IRT for smarter trials
With the role of automating patient randomisation and supply management, IRT is a critical backbone for trial execution, yet it…
-
Reducing white space in early development: Four regulatory pitfalls to avoid pre-IND
In a clinical development world divided by phases, transitions are critical at every step. The transition from nonclinical testing to…
-
Utilizing data-driven insights for digital health solutions
Digital health technologies are changing how care is delivered, but how do we substantiate claims that these innovations are effective?…
-
Regulatory factors in rare disease studies
The rare disease landscape poses myriad challenges for researchers, policymakers, and CROs, particularly in navigating its intricate regulatory environment. Rare…
-
Oncology trials: Delivering precision and reliability in data management
Clinical trials for oncology are filled with data management complexities that must be carefully navigated, with challenges and solutions outlined…
-
How better protocol design can reduce white space in clinical development
From the start of Phase I to the completion of Phase III, the average clinical trial cycle has been increasing…
-
The CGT frontier: what to prioritise in the transition from clinical to commercial
Projections show a $177.46 billion market by 2034 and an 18.7% CAGR. But here's the reality check: current manufacturing capacity…